Great Conference Call and Another Big Growth Year in 2016 -- The FDA approval of the migraine indication is about to happen. This company has a solid ongoing revenue stream that will expand significantly in 2017 and likely again for the next several years. The reason is simple. SUPN has "customers for life." The nonsense in Washington has little effect as these customers require constant daily medication. SUPN's epilepsy franchise is strong with Oxtellar XR, an extended-release oxcarbazepine; and Trokendi XR, an extended-release topiramate. Epilepsy patients and their docs appreciate the minimize side effects that this mandatory medicine has. The ADHD drug pipeline holds significant potential, too. This is a very important need, too. Prescriptions for Oxtellar and Trokendi continue to grow nicely, with patent protection exclusivity until 2023. There is a long clear runway to ramp up revenues ahead for SUPN when you look at the facts...not news blubs. With a forward P/E under 16 and quarterly revenue growth of 40+%, SUPN continues to be an investment gem, despite the day traders playing with the price around quarterly report time. SUPN is going higher.